Responsible Implementation of Genomic Testing for Rare Kidney Disorders

Prof.dr. Martina C Cornel
Professor of Community Genetics & Public Health Genomics
Department of Clinical Genetics
VU University Medical Center
Amsterdam, The Netherlands

Disclosure of Interests

Employment by

- VU University Medical Centre, Amsterdam, NL

where DNA-testing is performed for high risk of serious disorders for part of the Netherlands

No financial relationships with commercial companies (within last 3 years) related to the topic of this presentation
Overview

- Responsible implementation
  - Realize (some of) the promises to the tax payers
  - Do what we know in a responsible way
- Sequencing technologies
  - Many genes for a relatively low price
  - Unsolicited findings and Variants of Uncertain Significance
- Rare diseases
  - Data sharing and registries
2000: genome sequence published

Bill Clinton: We are here to celebrate the completion of the first survey of the entire human genome …

With this profound new knowledge, humankind is on the verge of gaining immense, new power to heal. Genome science will have a real impact on all our lives -- and even more, on the lives of our children.

It will revolutionize the diagnosis, prevention and treatment of most, if not all, human diseases.

Collins FS (Right at photo). Nature 2010 & © AP PHOTO/RON EDMONDS
Has the revolution arrived?

The consequences for clinical medicine, however, have thus far been modest.

Those who somehow expected dramatic results overnight may be disappointed, but should remember that genomics obeys the First Law of Technology: we invariably overestimate the short-term impacts of new technologies and underestimate their longer-term effects.
Responsible implementation

• **Efficient**
  • Waste of time, effort and finances are minimized

• **Effective**
  • Produces intended results

• **Robust and sustainable**
  • Anticipates changes in the future

• **Translating genome-based information into health care practice (Do what we know)**
Sequencing technologies

- More DNA tests available
- Price of DNA testing decreases
- Number of persons for whom DNA testing could potentially be relevant increases
- Fixed budgets
- Prioritization needed
- Mainstreaming needed
More tests for a lower price – better?

- Greater potential to identify the genetic component of health problem

Cartoon festival Knokke 2014
With permission of Borry & Matthijs
More tests for a lower price – better?

- Greater potential to identify the genetic component of health problem
- Unsolicited findings
  - BRCA in child with developmental delay
  - Kidney problem in child with multiple congenital anomalies
- VUS: Variants of uncertain significance

European Journal of Human Genetics (2013) 21, 580–584
© 2013 Macmillan Publishers Limited. All rights reserved 1018-4813/13
www.nature.com/ejhg

POLICY

Whole-genome sequencing in health care

Recommendations of the European Society of Human Genetics

Carla G van El1, Martina C Cornel1,2,3, Pascal Borry4, Ros J Hastings5, Florence Fellmann6, Shirley V Hodgson7, Heidi C Howard8,9, Anne Cambon-Thomsen8,9, Bartha M Knoppers10, Hanne Meijers-Heijboer11, Hans Scheffer12, Lisbeth Tranebjaerg13,14,15, Wybo Dondorp16,17, Guido MWR de Wert3,16,17

on behalf of the ESHG Public and Professional Policy Committee
Unsolicited findings

- Not an **incident**: the technology causes many UFs
- Not always **secondary**: sometimes no answer to the clinical question and yet some findings you were not looking for

- In the clinical context - challenges of handling vast amounts of information, most of which may not be directly relevant for the patient…

- Use filters to select relevant variants after sequencing .. not too soon or too restrictive .. hinder the diagnostic process
Unsolicited findings

Figure 1. Cooperation and communication between different parties involved in the informed consent procedure for NGS in diagnostics.

Rigter 2013 Hum Mutation
More analyses for a lower price – better?

(1) … should set up structures for sharing experiences and establish testing guidelines at local, national and international levels. *collective learning process*

(2) When in the clinical setting either targeted sequencing or analysis of genome data is possible, it is preferable to use a **targeted approach** first in order to avoid unsolicited findings or findings that cannot be interpreted. **Filtering** should limit the analysis to specific (sets of) genes. Known genetic variants with limited or no clinical utility should be filtered out (if possible neither analyzed nor reported).

(3) The use of genome-wide arrays or **WGA requires a justification** in terms of necessity (the need to solve a clinical problem) and proportionality (the balance of benefits and drawbacks for the patient).

*Van El, EJHG 2013*
Overview

- Responsible implementation
- Sequencing technologies
  - Many genes for a relatively low price
  - Unsolicited findings and Variants of Uncertain Significance
- Rare diseases
  - Data sharing and registries
Rare diseases

- After GWAS era (looking for associations of common diseases - common variants) NGS fits better!

- General principles
  
  - one test for anything (although expertise for analysis required)
  
  - increase of open access mentality - sharing data globally
    https://genomicsandhealth.org/

  - Mechanisms in place to find one more patient with same mutation – Global Alliance for Genomics and Health (GA4GH) – Matchmaker Exchange e.g.
About this Project

Matchmaker Exchange is a collaborative effort to address the common challenge of exome and genome sequencing in both the research and clinical settings wherein the majority of cases lack a clear etiology after initial analysis. For such cases, finding just a single additional case with a deleterious variant in the same gene and overlapping phenotype may provide sufficient evidence to identify the causative gene. Currently, multiple research and clinical laboratories and rare disease consortia independently collect data, but the result is fragmentation of efforts making the aggregation of similar cases difficult.

To address this challenge a meeting was organized by the International Rare Diseases Research Consortium (IRDIRC) and the Clinical Genome Resource (ClinGen) program, resulting in the launch of an open collaboration called the 'Matchmaker Exchange' in October 2013. This involves a large and growing number of teams and projects (see accompanying figure) working towards a federated platform (Exchange) to facilitate the matching of cases with similar phenotypic and genotypic profiles (matchmaking) through standardized application programming interfaces (APIs) and procedural conventions.

The Matchmaker Exchange project is being supported by the database participants involved as well as IRDIRC, ClinGen, and GA4GH.

Resources
Rare diseases

- Implementation requires **registration** – how can all children with condition XXX profit from new test or treatment?

- **Recontact?** Can we go back to patients?

- **Classification?** Morphology or relation to gene(response)?

- **Public or private?** Apart from open access models (GA4GH) also companies with registries, not all of which are shared.
Conclusion

- Many opportunities
- More is not always better: filter (limited resources)
- Organize settings for collective learning
- Register to know target group
- Think global